6LSU
 
 | | Crystal structure of Uso1-2 | | Descriptor: | Intracellular protein transport protein USO1 | | Authors: | Heo, Y.Y, Lee, H.H. | | Deposit date: | 2020-01-20 | | Release date: | 2021-01-27 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Crystal structures of Uso1 membrane tether reveal an alternative conformation in the globular head domain
Sci Rep, 10, 2020
|
|
5X8M
 | | PD-L1 in complex with durvalumab | | Descriptor: | Programmed cell death 1 ligand 1, durvalumab heavy chain, durvalumab light chain | | Authors: | Heo, Y.S, Lee, H.T. | | Deposit date: | 2017-03-03 | | Release date: | 2017-08-16 | | Method: | X-RAY DIFFRACTION (2.661 Å) | | Cite: | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
5X8L
 | | PD-L1 in complex with atezolizumab | | Descriptor: | Programmed cell death 1 ligand 1, atezolizumab heavy chain, atezolizumab light chain | | Authors: | Heo, Y.S, Lee, H.T. | | Deposit date: | 2017-03-03 | | Release date: | 2017-08-16 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
1UKH
 | | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 | | Descriptor: | 11-mer peptide from C-jun-amino-terminal kinase interacting protein 1, Mitogen-activated protein kinase 8 isoform 4 | | Authors: | Heo, Y.-S, Kim, Y.K, Sung, B.-J, Lee, H.S, Lee, J.I, Seo, C.I, Park, S.-Y, Kim, J.H, Hyun, Y.-L, Jeon, Y.H, Ro, S, Lee, T.G, Cho, J.M, Hwang, K.Y, Yang, C.-H. | | Deposit date: | 2003-08-23 | | Release date: | 2004-08-30 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (2.35 Å) | | Cite: | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
Embo J., 23, 2004
|
|
1UKI
 | | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 | | Descriptor: | 11-mer peptide from C-jun-amino-terminal kinase interacting protein 1, 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE, mitogen-activated protein kinase 8 isoform 4 | | Authors: | Heo, Y.-S, Kim, Y.K, Sung, B.-J, Lee, H.S, Lee, J.I, Seo, C.I, Park, S.-Y, Kim, J.H, Hyun, Y.-L, Jeon, Y.H, Ro, S, Lee, T.G, Cho, J.M, Hwang, K.Y, Yang, C.-H. | | Deposit date: | 2003-08-23 | | Release date: | 2004-08-30 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
Embo J., 23, 2004
|
|
6LST
 | | Crystal straucture of Uso1-1 | | Descriptor: | Intracellular protein transport protein USO1 | | Authors: | Heo, Y.Y, Lee, H.H. | | Deposit date: | 2020-01-20 | | Release date: | 2021-01-27 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.94 Å) | | Cite: | Crystal structures of Uso1 membrane tether reveal an alternative conformation in the globular head domain
Sci Rep, 10, 2020
|
|
5Y9J
 | | BAFF in complex with belimumab | | Descriptor: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | Authors: | Heo, Y.-S, Shin, W. | | Deposit date: | 2017-08-25 | | Release date: | 2018-02-21 | | Last modified: | 2019-09-04 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5Y9K
 | | Structure of the belimumab Fab fragment | | Descriptor: | belimumab heavy chain, belimumab light chain | | Authors: | Heo, Y.-S, Shin, W. | | Deposit date: | 2017-08-25 | | Release date: | 2018-02-21 | | Last modified: | 2019-09-04 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
7DCK
 | | Crystal structure of phosphodiesterase tw9814 | | Descriptor: | Lactamase_B domain-containing protein, MANGANESE (II) ION | | Authors: | Heo, Y, Yun, J.H, Park, J.H, Park, S.B, Cha, S.S, Lee, W. | | Deposit date: | 2020-10-26 | | Release date: | 2021-10-27 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.34 Å) | | Cite: | Structural and functional identification of the uncharacterized metallo-beta-lactamase superfamily protein TW9814 as a phosphodiesterase with unique metal coordination.
Acta Crystallogr D Struct Biol, 78, 2022
|
|
7CYU
 | | Crystal structure of human BAF57 HMG domain | | Descriptor: | SULFATE ION, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 | | Authors: | Heo, Y, Yun, J.H, Park, J.H, Lee, W. | | Deposit date: | 2020-09-04 | | Release date: | 2020-10-14 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.55 Å) | | Cite: | Crystal structure of the HMG domain of human BAF57 and its interaction with four-way junction DNA.
Biochem.Biophys.Res.Commun., 533, 2020
|
|
8GY5
 | |
8GSI
 | | Structure of the cobolimab Fab | | Descriptor: | heavy chain, light chain, nanobody | | Authors: | Heo, Y.S, Choi, S.B. | | Deposit date: | 2022-09-06 | | Release date: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (2.02 Å) | | Cite: | Crystal structure of the Fab fragment of cobolimab, an investigational antibody targeting Tim-3 for immune-oncology.
To Be Published
|
|
5GGV
 | | CTLA-4 in complex with tremelimumab Fab | | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (1.998 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGR
 | | PD-1 in complex with nivolumab Fab | | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (3.3 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGS
 | | PD-1 in complex with pembrolizumab Fab | | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (1.997 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGQ
 | | Crystal structure of Nivolumab Fab fragment | | Descriptor: | nivolumab heavy chain, nivolumab light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5WUX
 | | TNFalpha-certolizumab Fab | | Descriptor: | Tumor necrosis factor alpha, heavy, light | | Authors: | Heo, Y.S, Lee, J.U. | | Deposit date: | 2016-12-21 | | Release date: | 2017-06-07 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
5GGU
 | | Crystal structure of tremelimumab Fab | | Descriptor: | heavy chain, light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2016-11-16 | | Method: | X-RAY DIFFRACTION (2.292 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGT
 | | PD-L1 in complex with BMS-936559 Fab | | Descriptor: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | | Authors: | Heo, Y.S. | | Deposit date: | 2016-06-16 | | Release date: | 2016-11-09 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5WUV
 | | Crystal structure of Certolizumab Fab | | Descriptor: | heavy chain, light chain | | Authors: | Heo, Y.S, Lee, J.U, Son, J.Y, Shin, W, Yoo, K.Y. | | Deposit date: | 2016-12-21 | | Release date: | 2017-06-07 | | Method: | X-RAY DIFFRACTION (1.952 Å) | | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
4HQ6
 | | BC domain in the presence of citrate | | Descriptor: | Acetyl-CoA carboxylase 2 | | Authors: | Heo, Y.S. | | Deposit date: | 2012-10-25 | | Release date: | 2013-10-09 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structural Insights into the Regulation of ACC2 by Citrate
Bull.Korean Chem.Soc., 34, 2013
|
|
8HU2
 | | Rattus Syntenin-1 PDZ domain with inhibitor | | Descriptor: | (2~{S})-2-(9~{H}-fluoren-9-ylmethoxycarbonylamino)-3-(4-oxidanylidene-5~{H}-pyrimidin-2-yl)propanoic acid, Syntenin-1 | | Authors: | Heo, Y, Lee, J, Yun, J.H, Lee, W. | | Deposit date: | 2022-12-22 | | Release date: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Crystal structure of STNPDZ with inhibitor at 1.60 Angstroms resolution.
To Be Published
|
|
8WQJ
 | |
6JC2
 | | Crystal structure of the Fab fragment of ipilimumab | | Descriptor: | SULFATE ION, ipilimumab fab heavy chain, ipilimumab fab light chain | | Authors: | Heo, Y.S. | | Deposit date: | 2019-01-27 | | Release date: | 2019-09-11 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy
Bull.Korean Chem.Soc., 40, 2019
|
|
7BXA
 | | Crystal structure of PD-1 in complex with tislelizumab Fab | | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | | Authors: | Heo, Y.S, Lee, S.H, Lim, H, Lee, H.T, Kim, Y.J, Park, E.B. | | Deposit date: | 2020-04-18 | | Release date: | 2020-06-10 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (3.32 Å) | | Cite: | Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Biochem.Biophys.Res.Commun., 527, 2020
|
|
